3 completed, 1 recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
Follow PIK3CA-related Overgrowth Spectrum: new trials by email Literature Review of PIK3CA-related Overgrowth Spectrum trials Research Report on PIK3CA-related Overgrowth Spectrum
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations Alpelisib, Mirdametinib - Slow-Flow Vascular Malformation, Fast-Flow Vascular Malformation | Phase 2 | Recruiting | Murdoch Childrens Research Institute | 50 | 2024-09-13 | 2026-05-05 |
| A Study of the Epidemiology and Hospital Management of Patients With PROS in France PIK3CA-Related Overgrowth Spectrum | Completed | Novartis Pharmaceuticals | 3605 | 2024-01-15 | 2025-10-29 | |
| National Evaluation of Patients With PIK3CA-Related Overgrowth Spectrum (PROS) national registry - PIK3CA-related Overgrowth Spectrum, CLOVES Syndrome | Completed | Institut National de la Santé Et de la Recherche Médicale, France | 28 | 2023-02-21 | 2026-02-23 | |
| Health-related Quality of Life, Symptom Severity, and Pain Among Patients With PIK3CA-related Overgrowth Spectrum: A Mixed-methods Observational Study Alpelisib - PIK3CA-related Overgrowth Spectrum | Completed | Novartis Pharmaceuticals | 77 | 2022-05-16 | 2025-06-24 |
Hereditary Sensory and Autonomic Neuropathies (2) · Lymphatic Abnormalities (2) · Vascular Malformations (2) · Arteriovenous Malformations (1) · Congenital Lipomatous Overgrowth, Vascular Malformations, and Epidermal Nevi (1) · Klippel-Trenaunay-Weber Syndrome (1) · Lymphangioma (1) · Lymphangioma, Cystic (1) · Megalencephaly (1) · Megalodactyly (1) · Skin Diseases, Vascular (1)
Congenital Abnormalities (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Cardiovascular Abnormalities (2) · Cardiovascular Diseases (2) · Genetic Diseases, Inborn (2) · Hemic and Lymphatic Diseases (2) · Heredodegenerative Disorders, Nervous System (2) · Lymphatic Diseases (2) · Nervous System Diseases (2) · Nervous System Malformations (2) · Neurodegenerative Diseases (2) · Neuromuscular Diseases (2) · Peripheral Nervous System Diseases (2) · Polyneuropathies (2) · Vascular Diseases (2)
Alpelisib (2) · mirdametinib (1)
Novartis Pharmaceuticals (2) · Institut National de la Santé Et de la Recherche Médicale, France (1) · Murdoch Childrens Research Institute (1)
United States (2) · Australia (1) · France (1)
Guillaume Canaud, MD,PHD (1) · Lydia Pathmanathan, MBBS, FRACP. (1) · Stephen Luen, MBChB, FRACP. (1) · Tony Penington, MBBS, FRACS. (1)